公开(公告)号：US12122820B2

公开(公告)日：2024-10-22

申请号：US16988415

申请日：2020-08-07

申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： James L. Riley ,  Rachel Leibman ,  Aimee S. Payne ,  Christoph T. Ellebrecht ,  Michael C. Milone

IPC分类号： C07H21/04 ,  A61K35/17 ,  A61K38/17 ,  A61K39/42 ,  A61K45/06 ,  A61K48/00 ,  A61P31/18 ,  C07K14/705 ,  C07K14/725 ,  C07K14/73 ,  C07K16/10 ,  C12N15/63 ,  A01K67/00 ,  A61K39/00

CPC分类号： C07K14/70514 ,  A61K35/17 ,  A61K38/1774 ,  A61K39/42 ,  A61K45/06 ,  A61P31/18 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/1045 ,  A61K2039/505 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

摘要： The present invention relates to compositions and methods for treating of a HIV infected mammal using a CD4 membrane-bound chimeric receptor or a HIV specific scFvs CARs. One aspect includes a modified T cell and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with HIV infection.

公开(公告)号：US20240335538A1

公开(公告)日：2024-10-10

申请号：US18290668

申请日：2022-07-21

申请人： KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

发明人： Tae-Don KIM ,  Sooyun LEE

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K14/73 ,  C07K14/735 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C12N5/0783

CPC分类号： A61K39/464404 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4614 ,  A61K39/4615 ,  A61K39/4631 ,  A61K39/464406 ,  A61K39/464411 ,  A61K39/464419 ,  A61K39/464429 ,  A61K39/464466 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70532 ,  C07K14/70535 ,  C07K14/7056 ,  C07K14/70575 ,  C07K14/70578 ,  C07K14/70596 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/303 ,  C07K16/32 ,  C12N5/0646 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2510/00

摘要： The present invention relates to: a novel chimeric antigen receptor containing, as an intracellular signaling domain, an intracellular domain of a receptor containing a dead region; and immune cells expressing the chimeric antigen receptor. In environments in which normal cells are present, the immune cells expressing the chimeric antigen receptor according to the present invention exhibit little or no cytotoxicity and cell death of the immune cells is exhibited, thus ensuring the stability of the normal cells. Conversely, in environments in which target cells are present, the immune cells exhibit more potent cytotoxicity than with conventional techniques utilizing a lone chimeric antigen receptor.

公开(公告)号：US12063915B2

公开(公告)日：2024-08-20

申请号：US17031255

申请日：2020-09-24

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Lynn Macdonald ,  Andrew J. Murphy ,  Naxin Tu ,  Cagan Gurer

IPC分类号： A01K67/0278 ,  C07K14/705 ,  C12N5/0735 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/85 ,  C07K14/73 ,  C07K14/74

CPC分类号： A01K67/0278 ,  C07K14/70517 ,  C12N5/0606 ,  C12N5/0636 ,  C12N5/10 ,  C12N15/8509 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2267/03 ,  C07K14/70514 ,  C07K14/70539 ,  C07K2319/00 ,  C12N2517/02

摘要： The invention provides genetically modified non-human animals that express chimeric human/non-human T cell co-receptor polypeptides (e.g., CD4, CD8α, CD8β), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same.

公开(公告)号：US11976117B2

公开(公告)日：2024-05-07

申请号：US16826053

申请日：2020-03-20

申请人： McMaster University

发明人： Jonathan Lorne Bramson ,  Christopher W. Helsen ,  Joanne Alicia Hammill ,  Kenneth Anthony Mwawasi

IPC分类号： A61K35/17 ,  C07K14/73 ,  C07K16/28

CPC分类号： C07K16/2803 ,  C07K14/70514 ,  C07K16/2809 ,  C07K2317/622 ,  C07K2319/03

摘要： A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.

公开(公告)号：US11944647B2

公开(公告)日：2024-04-02

申请号：US17846868

申请日：2022-06-22

申请人： Juno Therapeutics, Inc.

发明人： Tina Albertson ,  Brian Christin ,  Jacob Randolph Garcia ,  Christopher Glen Ramsborg ,  Claire L. Sutherland ,  Clinton Weber ,  Rachel K. Yost ,  Mark J. Gilbert ,  He Li

IPC分类号： A61K35/17 ,  A61P35/00 ,  C07K14/705 ,  C07K14/73

CPC分类号： A61K35/17 ,  A61P35/00 ,  C07K14/70514 ,  C07K14/70517

摘要： Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.

公开(公告)号：US20230381232A1

公开(公告)日：2023-11-30

申请号：US18158770

申请日：2023-01-24

申请人： eFFECTOR Therapeutics Inc.

发明人： Kevin R. WEBSTER ,  Rajesh SHARMA ,  Gary CHIANG

IPC分类号： A61K35/17 ,  C07K14/74 ,  A61P35/00 ,  C07K14/725 ,  C07K14/73 ,  C07K14/16 ,  C07K14/705 ,  C12N5/0783 ,  C07D471/04 ,  C07D487/04 ,  C07D495/20 ,  C07D491/20 ,  C07D471/20 ,  A61K31/501

CPC分类号： A61K35/17 ,  C07K14/70539 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/162 ,  C07K14/70517 ,  C07K14/70589 ,  C07K14/70564 ,  C12N5/0638 ,  C07D471/04 ,  C07D487/04 ,  C07D495/20 ,  C12N5/0636 ,  C07D491/20 ,  C07D471/20 ,  A61K31/501 ,  A61K45/06

摘要： The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNK1, MNK2, or both are inhibited in the genetically modified T cell in order to enhance central memory T cell subsets in cellular immunotherapy compositions.

公开(公告)号：US20230365636A1

公开(公告)日：2023-11-16

申请号：US18029516

申请日：2021-11-16

申请人： Technische Universität München

发明人： Volker MORATH ,  Arne SKERRA ,  Wolfgang WEBER ,  Katja FRITSCHLE

IPC分类号： C07K14/47 ,  C12N15/86 ,  G01N33/566 ,  C07K14/73 ,  C07K14/705 ,  A61K51/08 ,  A61K51/04

CPC分类号： C07K14/47 ,  C12N15/86 ,  G01N33/566 ,  C07K14/70514 ,  C07K14/70521 ,  A61K51/08 ,  A61K51/0497 ,  C12N2750/14143 ,  C07K2319/035 ,  C07K2319/03 ,  C07K2319/60

摘要： The present invention relates to a nucleic acid molecule encoding a fusion protein comprising (i) a secretory signal peptide; (ii) a lipocalin-derived binding protein specifically binding to an exogenous ligand; and (iii) a glycosylphosphatidylinositol (GPI) anchored and/or transmembrane domain.

公开(公告)号：US11807662B2

公开(公告)日：2023-11-07

申请号：US16614005

申请日：2018-05-16

申请人： The Johns Hopkins University

发明人： Emily Han-Chung Hsiue ,  Qing Wang ,  Bert Vogelstein ,  Kenneth W. Kinzler ,  Shibin Zhou ,  Jacqueline Douglass ,  Michael S. Hwang ,  Nickolas Papadopoulos

IPC分类号： A61K39/395 ,  C07K16/28 ,  A61K35/17 ,  C07K14/725 ,  C07K14/73 ,  C07K14/705 ,  A61K38/00

CPC分类号： C07K16/2833 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/70517 ,  C07K14/70521 ,  C07K16/2809 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/622 ,  C07K2319/03

摘要： This document provides methods and materials for assessing a mammal having or suspected of having cancer and/or for treating a mammal having cancer. For example, molecules including one or more antigen-binding domains (e.g., a single-chain variable fragment (scFv)) that can bind to a modified peptide (e.g., a tumor antigen), as well as method for using such molecules, are provided.

公开(公告)号：US20230277668A1

公开(公告)日：2023-09-07

申请号：US18017696

申请日：2021-06-11

申请人： CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES

发明人： CHENQI XU ,  QIUPING ZHOU ,  WEI WU ,  XINYI XU ,  XING HE

IPC分类号： A61K39/00 ,  C07K16/28 ,  C07K14/705 ,  C07K14/73 ,  A61P35/00

CPC分类号： A61K39/4631 ,  C07K16/2809 ,  C07K14/70521 ,  C07K14/70578 ,  C07K14/70517 ,  C07K14/70514 ,  C07K16/2803 ,  A61K39/4611 ,  A61P35/00 ,  C07K2317/53

摘要： A chimeric antigen receptor containing a CD3ε intracellular region with a Y/F mutation, includes an extracellular domain, a transmembrane domain, and an intracellular domain which are connected in sequence, where one end of the intracellular domain, which is connected to the transmembrane domain, is connected to the CD3ε intracellular region with the Y/F mutation, and the CD3ε intracellular region with the Y/F mutation refers to a Y/F mutant CD3ε intracellular region in which both tyrosines are mutated to phenylalanines in the ITAM of the CD3ε intracellular region. T cells modified with the chimeric antigen receptor have improved viability, decreased apoptosis level, and increased proliferation ability, and down-regulate the expression levels of cytokines IFN-γ and TNF-α.

公开(公告)号：US20230167191A1

公开(公告)日：2023-06-01

申请号：US17920724

申请日：2021-04-23

申请人： Sorrento Therapeutics, Inc.

发明人： Henry Hongjun Ji ,  Runqiang Chen ,  Xiaomei Yuan

IPC分类号： C07K16/28 ,  C07K14/725 ,  C07K14/715 ,  C07K14/73 ,  C07K14/705 ,  A61K48/00 ,  A61K35/17

CPC分类号： C07K16/2896 ,  C07K14/7051 ,  C07K14/7155 ,  C07K14/70514 ,  C07K14/70521 ,  A61K48/005 ,  A61K35/17 ,  C07K2319/00 ,  A61K38/00

摘要： The present disclosure provides transgenic cells that express memory dimeric antigen receptors (mDARs), where the mDAR constructs comprise a JAK-STAT intracellular region having a cytokine receptor intracellular region which includes Box 1 and Box 2 motifs for binding a Janus kinase (JAK) which can play a role in JAK-STAT cellular signaling pathway to induce effector cell activation and proliferation. In one embodiment, the JAK-STAT intracellular region further comprises a CD3zeta intracellular signaling region having an intact ITAM region, or having ITAM 1 and 3, or having only ITAM 3 with a partial deletion. Transgenic cells expressing the mDAR constructs exhibit potent cytotoxicity, and release reduced levels of cytokines, compared to traditional DARs that lack a cytokine receptor intracellular region. The mDAR constructs have antibody-like properties as they bind specifically to a target antigen. Transgenic cells expressing the mDAR constructs can be used for directed cell therapy.